Paradoxical exacerbation o

e1 ile profiles [1]. It is currently licensed in the USA as adjunct- renamed as epilepsy with myoclonic-atonic seizures and Makke et al. BMC Pediatrics (2015) 15:6 DOI 10.1186/s12887-015-0330-yLEV efficacy against myoclonic seizures has led to its off label use in a variety of conditions associated with Beirut, Lebanon Full list of author information is available at the end of the articleive therapy for the treatment of partial onset seizures in patients one month of age and older, myoclonic seizures in patients 12 years and older diagnosed with juvenile myoclonic epilepsy [2] and primarily generalized tonic-clonic seizures in patients 6 years and older diagnosed with an idiopathic generalized epilepsy [3]. classified as one of the childhood onset electroclinical syn-dromes [6]. It is a generalized epilepsy, typically affecting developmentally normal children with a mean age at onset of 2–4 years and is clinically characterized by the occur-rence of myoclonic, atonic, myoclonic-atonic and absence seizures which are usually preceded by febrile or afebrile generalized tonic-clonic seizures. The EEG is character-ized by a normal background with bursts of generalized 2–4 Hz spike or polyspike wave discharges. * Correspondence